Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 1995; 74(01): 338-344DOI: 10.1055/s-0038-1642699 Symposium Antiphospholipid Antibodies Schattauer GmbH Stuttgart Diagnostic Methodologies for Circulating Anticoagulants Thomas Exner Haematology Department, Westmead Hospital, Westmead, Australia › Institutsangaben Artikel empfehlen Abstract als PDF herunterladen Artikel einzeln kaufen PDF (481 kb) Referenzen Reference 1 Feinstein DL, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Haemostas Thromb 1972; 1: 75-95 2 Brandt JT. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemostas. 1995 In press 3 Triplett DA. Assays for the detection of antiphospholipid antibodies. Lupus 1994; 3: 281-287 4 Exner T, Triplett DA, Tabemer D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemostas 1991; 65: 320-325 5 Clyne LP, Yen Y, Kriz NS, Breitenstein MG. The lupus anticoagulant: High incidence of negative mixing studies in a human immunodeficiency viruspositive population Arch Pathol Lab Med. 1993; 117: 595-602 6 Ciaudo M, Horellou MH, Audovin J. Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen: A report of four patients. Am J Hemat 1991; 38: 271-276 7 Green D. Acquired inhibitors of coagulation. In: Haemostasis and Thrombosis. Bloom A, Thomas D. eds. 1989; 542-553 8 Green D, Lechner K. A survey on 215 non-haemophilic patients with inhibitors to factor VIII. Thromb Haemostas 1981; 45: 200-203 9 Love PE, Santoro SA. Antiphospholipid antibodies : Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders Ann Int Med. 1990; 112: 682-698 10 Bellotti V, Gamba G, Merlini G. Study of three patients with monoclonal gammopathies and lupus-like anticoagulants. BrJ Haematol 1989; 73: 221-227 11 Keyser JW. Human Plasma Proteins: Their investigation and pathological conditions - 2nd ed. John Wiley & Sons Ltd 1987; 41 12 Jude B, Goudemand J, Dolle I, Caron C, Watel A, Tiry C, Cosson A. Lupus anticoagulant: A clinical and laboratory study of 100 cases. Clin Lab Haemat 1988; 10: 41-51 13 Berube C, David M, Laxer R. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus in children: A cross sectional study. Lupus 1994; 3: 360 (abst 190) 14 Margolius Jr A, Jackson DP, Ratnoff OD. Circulating anti coagulants: A study of the literature. Medicine 1961; 40: 145-202 15 Rosner R, Pauzner R, Lusky A. Detection and quantitative evaluation of lupus circulating anti-coagulant activity. Thromb Haemostas 1987; 57: 144-147 16 Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ W. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985; 19: 265-275 17 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151 18 O’Neil Al, Abrahim KM A, Parkin JD. Automation of the kaolin clotting time. Pathology 1992; 24: 12-14 19 Chantarangkul V, Tripodi A, Arbini A, Mannucci PM. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res 1992; 67: 355-365 20 Rosove MH, Ismail M, Kozoil BJ, Runge A, Kasper CK. Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood 1986; 68: 472-478 21 Saxena R, Saraya AK, Kottle VK, Singh YN, Prasad L, Malviya AN. Inosithin neutralization test to measure lupus anticoagulants. Am J Clin Pathol 1993; 99: 61-64 22 Adcock DM, Marlar RA. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant. Arch Path Lab Med 1992; 116: 837-840 23 Alving BM, Baldwin PF, Richards RI, Jackson BJ. The dilute phospholipid APTT: A sensitive assay for verification of lupus anticoagulants. Thromb Haemostas 1985; 54: 709-712 24 Blanco AN, Grand BE, Pieroni G, Penalva LB, Voto LS, Lazzari MA. Behaviour of diluted activated partial thromboplastin time in pregnant women with a lupus anticoagulant. Am J Clin Pathol 1993; 100: 99-102 25 Brandt JT, Triplett DA, Rock WA. Effect of lupus anticoagulant on the activated partial thromboplastin time. Arch Pathol Lab Med 1991; 115: 109-114 26 Triplett DA, Brandt JT, Kaczor D. Laboratory diagnosis oflupus inhibitors; a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682 27 Carroll P, Ray M, Just S, Hawson G. A lupus anticoagulant neutralization procedure using the patients own platelets. Bl Coag Fblys 1994; 5: 523-527 28 Amout J, Huybrechts E, Vanmsselt M, Vermylen J. A new lupus anticoagulant neutralization test based CHI platelet derived vesicles. Br J Haematol 1992; 80: 341-346 29 Exner T, Rickard KA, Kronenberg H. Studies on phospholipids in the action of a lupus coagulation inhibitor. Pathology 1975; 7: 319-328 30 Harlos K, Eibl H. Hexagonal phases in phospholipids with saturated chains: Phosphatidylethanolamines and phosphatidic acids. Biochemistry 1981; 20: 2888-2892 31 Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from antifactor antibodies using hexagonal phase II phospholipids. Thromb Haemostas 1989; 62: 892-896 32 Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemostas 1993; 70: 787-793 33 Stevenson KJ, Seddon JM. The role of lipids in the detection of lupus anticoagulants by the dilute Russell Viper venom test: Are platelets or reagents containing hexagonal phases necessary?. Br J Haematol 1994; 86: 583-589 34 Robert A. Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant. Thromb Haemostas 1994; 71: 220-224 35 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509 36 Amout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94-99 37 Liu HW, Wong KC, Lin CK. The reappraisal of dilute tissue thromboplastin inhibition test in the diagnosis of lupus anticoagulant. Br J Haematol 1989; 72: 229-234 38 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis oflupus anticoagulant. Blood 1986; 68: 869-874 39 Exner T, Triplett DA, Tabemer DA, Machin S. Comparison of test methods for the lupus anticoagulant:Intemational Survey on Lupus Anticoagulants -1 (ISLA-1). Thromb Haemostas 1990; 64: 478-484 40 Exner T, Papadopoulos G, Koutts J. Use of a simplified dilute Russell viper venom time confirms heterogeneity among “lupus anticoagulants”. B1 Coag Fblys 1990; 1: 259-266 41 Schjetlein R, Sletnes KE, Wisloff F. A quantitative semi-automated and computer-assisted test for lupus anticoagulant. hromb Res 1993; 68: 869-874 42 Rooney AM, McNally T, Mackie IJ. The Taipan snake venom time: a new test for lupus anticoagulant. J Clin Pathol 1994; 47: 497-501 43 Triplett DA, Stocker KF, Unger GA, Bama LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70: 925-931 44 Exner T. Similar mechanisms of various lupus anticoagulants. Thromb Haemostas 1985; 53: 15-18 45 Brandt JT. Assays for phospholipid-dependent formation of thrombin and Xa: A potential method for quantifying lupus anticoagulant activity. Thromb Haemostas 1991; 66: 453-458 46 Galli M, Bevers EM. Inhibition of phospholipid-dependent coagulation reactions by ‘Antiphospholipid Antibodies’: Possible mechanisms of action. Lupus 1994; 3: 223-228 47 Amout J, Huybrechts E, Vanmsselt M, Falcon C, Vermylen J. Detection of lupus-like anticoagulants by an enzyme linked immunosorbent assay using a partial thromboplastin as antigen; a comparative study. Thromb Haemostas 1990; 64: 26-31 48 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: beta-2-glycoprotein (apolipoprotein H). Proc Natl Acad Sci 1990; 87: 4120-4124 49 Cowchock FS. Can tests for IgA, IgG or IgM antibodies to cardiolipin or phosphatidyl serine substitute for lupus anticoagulant assays in screening for antiphospholipid antibodies?. Autoimmunity 1994; 17: 119-122 50 Exner T, Sahman N, Trudinger B. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid polystyrene column. Biochem Biophys Res Commun 1988; 155: 1001-1007 51 McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989; 73: 506-513 52 Galli M, Comfurius P, Barbui T. Anticoagulant activity of b2Glycoprotein 1 is potentiated by a distinct sub-group of anticardiolipin antibodies. Thromb Haemostas 1992; 68: 297-300 53 Costing JD, Deiksen RH W M, Entjes HT. Lupus anticoagulant activity is frequently dependent on the presence of β2Glycoprotein 1. Thromb Haemostas 1992; 67: 499-502 54 Brandt JT. Antibodies to b2Glycoprotein 1 inhibit phospholipid dependent coagulation reactions. Thromb Haemostas 1993; 70: 598-602 55 Wagenknecht DR, McIntyre JA. Changes in β2Glycoprotein 1 antigenicity induced by phospholipid binding. Thromb Haemostas 1993; 69: 361-365 56 Kandiah DA, Krilis SA. Beta2 Glycoprotein 1. Lupus 1994; 3: 207-212 57 Schousboe I. Beta-2-glycoprotein 1: a plasma inhibitor of the contact activation of the intrinsicblood coagulation pathway. Blood 1985; 66: 1086-1091 58 Bevers EM, Galli M, Barbui T. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemostas 1991; 66: 629-632 59 Permpikul P, Rao L VM, Rapaport SI. Functional and binding studies of the roles of prothrombin and β2Glycoprotein 1 in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-2892
